drugset / Trial / NCT02200991
Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine
RandomizedParallel-groupOpen-labelTreatment
Summary
Primary Objective: To demonstrate significant reduction in postprandial plasma glucose (ΔAUC0:30-4:30h) after a standardized breakfast from baseline to Day 29. Secondary Objectives: To demonstrate: * Changes from baseline to Day 29 in maximum postprandial plasma glucose excursion, C-peptide and glucagon levels after a standardized breakfast * Delaying gastric emptying (13C-acetic acid breath test) * Safety and tolerability
Timeline
- Start
- 2014-08
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lixisenatide | Peptide | 20 ug | Subcutaneous |
| Comparator | Sitagliptin | Small molecule | 50 mg | Oral |
| Background | insulin glargine | Protein / enzyme biologic | — | Subcutaneous |